Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.82 GBX | +5.56% | -1.64% | +9.85% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.81M | Sales 2025 * | 3.28M 4.1M | Capitalization | 6.36M 7.96M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.2 x |
Net cash position 2024 * | 3.66M 4.58M | Net cash position 2025 * | 2.95M 3.69M | EV / Sales 2025 * | 1.04 x |
P/E ratio 2024 * |
-2.36
x | P/E ratio 2025 * |
-6.83
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 day | +5.56% | ||
1 week | -1.64% | ||
Current month | +20.22% | ||
1 month | +12.42% | ||
3 months | -12.03% | ||
6 months | -18.34% | ||
Current year | +9.85% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 21-11-30 |
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John McKenna
BRD | Director/Board Member | 71 | 16-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 21-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 10.82 | +5.56% | 344 923 |
24-04-25 | 10.25 | 0.00% | 246,695 |
24-04-24 | 10.25 | -4.65% | 577,459 |
24-04-23 | 10.75 | 0.00% | 53,279 |
24-04-22 | 10.75 | -2.27% | 276,581 |
Delayed Quote London S.E., April 26, 2024 at 08:32 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.85% | 7.95M | |
+7.71% | 218B | |
+6.25% | 182B | |
+10.60% | 132B | |
+26.73% | 108B | |
+15.42% | 52.98B | |
-1.89% | 47.59B | |
-1.91% | 39.96B | |
+11.16% | 39.22B | |
+6.63% | 26.94B |
- Stock Market
- Equities
- AOR Stock